Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Natalizumab (ausschließlich Darreichungsform ILO), ATC L04AA23 für die Zeit 01.09.2026 - 31.08.2028

Section 130a, Paragraph 8, SGB V allows health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-specific, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Natalizumab (exclusively in the ILO dosage form), ATC L04AA23, the DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the authorisation model for the aforementioned active substance comes into force for the first time on 01.09.2026 and expires on 31.08.2028. It ends automatically with the entry into force of the exclusive contract, regardless.